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Abstract
© 2018  Media  Sphera  Publishing  Group.  All  rights  reserved.  European  Registry  on  the
management  of  Helicobacter  pylori  infection  («Hp-EuReg»)  -  a  multicenter  prospective
observational  study  initiated  by  the  European  Helicobacter  and  Microbiota  Study  Group,
conducted in 27 European countries in order to evaluate the real clinical practice of diagnosis
and treatment of H. pylori and its comparison with international recommendations. Materials
and methods. The analysis of 2360 patients entered in the register by the Russian centres of
«Hp-EuReg» in 2013-2017, who were underwent 1st line eradication therapy. Results. The most
common methods of primary diagnosis of H. pylori are histological (37.7%), rapid urease test
(29.2%) and serology (29.7%). The duration of eradication therapy in 9.4% of cases was 7 days,
in 65.3% - 10 days, and in 25.3% - 14 days. To control the effectiveness of treatment, H. pylori
antigen in feces (31.3%), urea breath test (23.4%) and histological method (23.3%) were used.
In 3.6% cases was used serology by mistake. In 17.3% of patients control was not carried out.
The effectiveness of triple therapy with a PPI, amoxicillin, clarithromycin (per protocol) was
67.6%, with 7-day course, 81.1% at 10-day and 86.7% at 14-day course. Åradication rate of
triple therapy with addition of bismuth (per protocol) reached 90,6% in the group receiving 10-
day scheme and 93.6% in the group receiving the 14-day treatment. Conclusion. Significant
deviations of clinical practice from expert recommendations, most pronounced at the stage of
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